Cure51 raises a €15 million seed round led by Sofinnova Partners to harness the natural power of cancer survivors and contribute to curing the disease.
Cure51 raises a €15 million seed round led by Sofinnova Partners to harness the natural power of cancer survivors and contribute to curing the disease.
03/20/24, 8:06 AM
Location
parisMoney raised
€15 million
Industry
medical
biotechnology
health care
Round Type
seed
Investors
Olivier Pomel, Xavier Niel, Life Extension Ventures, Hitachi Ventures Gmb H, Sofinnova Partners
Cure51 announced a successful €15 million seed funding round led by Sofinnova Partners. Other investors included Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog. The funding will enable Cure51 to build a unique cohort exploring the molecular processes by which certain cancer patients survive for extended periods despite having highly aggressive forms of the disease.
Company Info
Location
paris, ile de france, france
Additional Info
Cure51 is a French "TechBio" company founded by Nicolas Wolikow and Simon Istolainen, alongside seasoned entrepreneurs and four world-renowned oncology centers: Gustave Roussy Institute (IGR, Paris - France ), Leon Bérard Center (CLB, Lyon - France ), Charité Universitätsmedizin ( Berlin - Germany ) and Vall d' Hebron (VHIO, Barcelona - Spain ). The collaboration between the private and public sectors is at the core of the Cure51 project, led by a passionate team with expertise in computing, medicine, and biology, and partnered with principal investigators across its network of over 50 leading oncology centers worldwide.